Key result
Higher long-chain sphingolipids linked to poorer cardiopulmonary fitness, while reductions correlate with improved VO2peak.
Why the study?
The association between peripheral sphingolipids and cardiopulmonary fitness in CAD patients undergoing cardiac rehabilitation was not well defined.
Cohort (n=100)
No
Effect estimate: β = -0.26
p-value: p=0.01
Sphingolipids may track fitness changes during CAD rehabilitation; leaves open their value as intervention targets.
The long-term benefits conferred by cardiac rehabilitation (CR) in those with coronary artery disease (CAD) are strongly linked with an improvement in cardiopulmonary fitness. This study aimed to determine the association between peripheral sphingolipids and cardiopulmonary fitness in CAD subjects undertaking CR. Patients with CAD (n = 100, mean age = 64 ± 6 years, 85% male, mean years of education = 17 ± 3 years) underwent 6 months of CR with blood collected at baseline, 3 and 6 months. Cardiopulmonary fitness was assessed by measuring peak oxygen uptake (VO2peak) at all time points. High performance liquid chromatography coupled electrospray ionization tandem mass spectrometry was used to quantify plasma sphingolipid concentrations. Cross-sectional and longitudinal associations between sphingolipids and VO2peak were assessed using linear regressions and mixed models, respectively. Higher concentrations of sphingomyelin C18:1 (β = -0.26, p = .01), ceramides C16:0 (β = -0.24, p = .02), C18:0 (β = -0.29, p = .002), C20:0 (β = -0.24, p = .02) and C24:1 (β = -0.24, p = .01) and monohexylceramide C18:0 (β = -0.23, p = .02) were associated with poorer VO2peak at baseline. An improvement in VO2peak was associated with a decrease in sphingomyelin C18:1 (b = -10.09, p = .006), ceramides C16:0 (b = -9.25, p = .0003), C18:0 (b = -5.44, p = .0003) and C24:1 (b = -2.46, p = .006) and monohexylceramide C18:0 (b = -5.37, p = .005). Specific long chain sphingolipids may be useful markers of fitness and response to exercise in CAD.
No takes yet. Share an insight, caveat, or question.
Saleem et al. (2018) conducted a cohort in Coronary Artery Disease (CAD) (n=100). Peripheral sphingolipids (e.g., sphingomyelin C18:1, ceramides C16:0, C18:0) was evaluated on Peak oxygen uptake (VO2peak) at baseline (β = -0.26, p=0.01). Higher baseline concentrations of specific long-chain sphingolipids, such as sphingomyelin C18:1 (β = -0.26), were associated with poorer cardiopulmonary fitness, and their decrease over 6 months correlated with improved VO2peak (b = -10.09).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: